Survival impact and safety comparison of pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A meta-analysis

Hafiz Muhammad Ehsan Arshad; Faaz Ali; Anas Babar; Muhammad Zain Raza; Musab Maqsood; Akmal Ameer

doi:10.36141/svdld.vi.16432

Authors

Hafiz Muhammad Ehsan Arshad Department of Medicine and Surgery, King Edward Medical University, Lahore, Pakistan https://orcid.org/0009-0007-3629-525X
Faaz Ali Department of Medicine and Surgery, King Edward Medical University, Lahore, Pakistan https://orcid.org/0009-0009-0835-611X
Anas Babar Department of Medicine and Surgery, King Edward Medical University, Lahore, Pakistan https://orcid.org/0009-0009-2179-1300
Muhammad Zain Raza Department of Medicine and Surgery, King Edward Medical University, Lahore, Pakistan https://orcid.org/0009-0004-3808-5991
Musab Maqsood Department of Medicine and Surgery, King Edward Medical University, Lahore, Pakistan https://orcid.org/0009-0008-2220-2902
Akmal Ameer Department of Medicine and Surgery, University Hospital Limerick, Ireland https://orcid.org/0009-0003-2195-089X

Keywords:

Idiopathic Pulmonary Fibrosis, Nintedanib, Pirfenidone, Anti-fibrotic therapy

Abstract

Background and aim: Idiopathic pulmonary fibrosis (IPF) is a severe restrictive lung disease affecting approximately 3 million people worldwide with two approved antifibrotics, nintedanib and pirfenidone, available for use. This review aims to compare their survival impact and safety profile.

Methods: Two databases and two trial registers along with additional sources were searched for cohorts reporting IPF patients of any age or stage, receiving either pirfenidone or nintedanib. The Inverse-Variance and Mantel-Haenszel method along with either a fixed- or random-effects model was used for analysing survival and other dichotomous outcomes, respectively.

Results: 23 cohorts were included. The pooled analysis showed that compared to pirfenidone, nintedanib group had similar survival (HR=1.12; 95%-CI:0.99-1.27; P=0.07), all-cause mortality (OR=1.11; 95%-CI:0.94-1.31; P=0.22), drug switches (OR=1.82; 95%-CI:0.69-4.78; P=0.22), and treatment discontinuations (OR=0.92; 95%-CI:0.60-1.41; P=0.70), higher odds of diarrhoea (OR=12.39; 95%-CI: 5.67-27.07; P<0.00001) and abnormal liver-function tests (OR=2.98; 95%-CI:1.92-4.61; P<0.00001), and lower odds of photosensitivity (OR=0.06; 95%-CI:0.01-0.25; P=0.0001), and skin-rash (OR=0.17; 95%-CI:0.08-0.34; P<0.00001).

Conclusions: While both treatment groups had similar overall survival and all-cause mortality, the safety profiles of nintedanib and pirfenidone differed significantly, with nintedanib being associated with greater odds of liver toxicity and diarrhoea, and pirfenidone with photosensitivity and skin rash, suggesting they could be favoured in slightly distinct population groups. Further research is necessary to refine the current comprehension of these drugs and their optimal utilization in IPF treatment, particularly taking into account factors such as disease stage and sequential therapy

References

1. Koudstaal T, Wijsenbeek MS. Idiopathic pulmonary fibrosis. Presse Médicale. 2023;52(3):104166. doi:10.1016/j.lpm.2023.104166

2. Smith ML. The histologic diagnosis of usual interstitial pneumonia of idiopathic pulmonary fibrosis. Where we are and where we need to go. Mod Pathol. 2022;35:8-14. doi:10.1038/s41379-021-00889-5

3. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68. doi:10.1164/rccm.201807-1255ST

4. Monteleone G, ILDs Study Group Sip/Irs null, Bergantini L, et al. The management of Familial Pulmonary Fibrosis in different medical settings: Where does that leave us? An Italian nationwide survey. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 2024;41(3):e2024047. doi:10.36141/svdld.v41i3.15744

5. Duhig EE. Usual interstitial pneumonia: a review of the pathogenesis and discussion of elastin fibres, type II pneumocytes and proposed roles in the pathogenesis. Pathology (Phila). 2022;54(5):517-25. doi:10.1016/j.pathol.2022.05.002

6. Honda T, Uehara T, Sano K. Heterogeneous proliferation of type II pneumocytes in usual interstitial pneumonia. Pathology (Phila). 2006;38(5):433-6. doi:10.1080/00313020600922462

7. Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192(2):e3-e19. doi:10.1164/rccm.201506-1063ST

8. Tepede A, Yogaratnam D. Nintedanib for Idiopathic Pulmonary Fibrosis. J Pharm Pract. 2019;32(2):199-206. doi:10.1177/0897190017735242

9. Aimo A, Spitaleri G, Nieri D, et al. Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond. Card Fail Rev. 2022;8:e12. doi:10.15420/cfr.2021.30

10. Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13-9. doi:10.1016/j.ejps.2014.02.014

11. Bocchino M, Bruzzese D, Scioscia G, et al. Disease stage-related survival in idiopathic pulmonary fibrosis patients treated with nintedanib and pirfenidone: An exploratory study. Respir Med Res. 2023;84:101013. doi:10.1016/j.resmer.2023.101013

12. Richeldi L, Bois RM du, Raghu G, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370(22):2071-82. doi:10.1056/NEJMoa1402584

13. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. The Lancet. 2011;377(9779):1760-9. doi:10.1016/S0140-6736(11)60405-4

14. King TE, Bradford WZ, Castro-Bernardini S, et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370(22):2083-92. doi:10.1056/NEJMoa1402582

15. Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33-41. doi:10.1016/S2213-2600(16)30326-5

16. Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74-9. doi:10.1016/j.rmed.2016.02.001

17. Man RK, Gogikar A, Nanda A, et al. A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review. Cureus. 16(2):e54268. doi:10.7759/cureus.54268

18. Chianese M, Screm G, Salton F, et al. Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows. Pharm Basel Switz. 2024;17(6):709. doi:10.3390/ph17060709

19. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-e47. doi:10.1164/rccm.202202-0399ST

20. Wells G, Shea B, Connell DO, Petersn J, Welch V. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. Accessed: July 29, 2025. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

21. Granholm A, Alhazzani W, Møller MH. Use of the GRADE approach in systematic reviews and guidelines. Br J Anaesth. 2019;123(5):554-9. doi:10.1016/j.bja.2019.08.015

22. Barratt SL, Mulholland S, Al Jbour K, et al. South-West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). Front Pharmacol. 2018;9:1480. doi:10.3389/fphar.2018.01480

23. Belhassen M, Dalon F, Nolin M, Van Ganse E. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. Respir Res. 2021;22(1):135. doi:10.1186/s12931-021-01714-y

24. Cameli P, Refini RM, Bergantini L, et al. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study. Front Mol Biosci. 2020;7:581828. doi:10.3389/fmolb.2020.581828

25. Corral M, DeYoung K, Kong AM. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study. BMC Pulm Med. 2020;20(1):188. doi:10.1186/s12890-020-01224-5

26. Dempsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH. Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019;200(2):168-74. doi:10.1164/rccm.201902-0456OC

27. Fournier D, Jouneau S, Bouzillé G, Polard E, Osmont MN, Scailteux LM. Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients. Pulm Pharmacol Ther. 2022;76:102149. doi:10.1016/j.pupt.2022.102149

28. Galli JA, Pandya A, Vega-Olivo M, Dass C, Zhao H, Criner GJ. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions. Respirol Carlton Vic. 2017;22(6):1171-8. doi:10.1111/resp.13024

29. Holtze CH, Freiheit EA, Limb SL, et al. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry. Respir Res. 2020;21(1):48. doi:10.1186/s12931-020-1315-4

30. Honda K, Saraya T, Ishii H. A Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A Special Reference to the Role of Antifibrotic Agents for the Elderly. J Clin Med. 2023;12(10). doi:10.3390/jcm12103564

31. Iwasaki K, Wakabayashi H, Saiki A, Ueshiba H, Murakami Y, Matsuzawa Y. Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan. Drugs - Real World Outcomes. 2024;11(1):43-52. doi:10.1007/s40801-023-00396-w

32. Khan MA, Ghamdi BA, Alhamadi M, et al. A survival analysis of idiopathic pulmonary fibrosis in the context of antifibrotic therapy in Saudi Arabia. Ann Thorac Med. 2023;18(2):79-85. doi:10.4103/atm.atm_264_22

33. Khan MA, Sherbini N, Alyami S, et al. Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data. Ann Thorac Med. 2023;18(1):45-51. doi:10.4103/atm.atm_206_22

34. Levra S, Guida G, Sprio AE, et al. Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience. Biomedicines. 2022;10(12). doi:10.3390/biomedicines10123229

35. Marijic P, Schwarzkopf L, Schwettmann L, Ruhnke T, Trudzinski F, Kreuter M. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study. Respir Res. 2021;22(1):268. doi:10.1186/s12931-021-01857-y

36. Noor S, Nawaz S, Chaudhuri N. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment. Adv Ther. 2021;38(1):268-77. doi:10.1007/s12325-020-01523-7

37. Takehara K, Koga Y, Hachisu Y, et al. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Cells. 2022;11(1). doi:10.3390/cells11010143

38. Üzer F, Akanlar S, Çilli A. Real-life data in the treatment and follow-up of idiopathic pulmonary fibrosis: A single-center study. Tuberk Ve Toraks. 2023;71(4):347-55. doi:10.5578/tt.20239603

39. Wright WA, Crowley LE, Parekh D, et al. Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2021;8(1):e000782. doi:10.1136/bmjresp-2020-000782

40. Romero Ortiz AD, Jiménez-Rodríguez BM, López-Ramírez C, et al. Antifibrotic treatment adherence, efficacy and outcomes for patients with idiopathic pulmonary fibrosis in Spain: a real-world evidence study. BMJ Open Respir Res. 2024;11(1). doi:10.1136/bmjresp-2023-001687

41. Sadon AAEA, Kenawy AS, Abdelsalam AH, Attia HM. Pirfenidone vs nintedanib for treatment of idiopathic pulmonary fibrosis in clinical practice: efficacy, tolerability, and adverse effects. Egypt J Chest Dis Tuberc. 2020;69(3):549. doi:10.4103/ejcdt.ejcdt_140_19

42. Zhao R, Xie B, Wang X, et al. The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study. Pulm Pharmacol Ther. 2024;84:102287. doi:10.1016/j.pupt.2024.102287

43. Cerri S, Monari M, Guerrieri A, et al. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment. Respir Med. 2019;159:105803. doi:10.1016/j.rmed.2019.105803

44. Paterniti MO, Bi Y, Rekić D, Wang Y, Karimi-Shah BA, Chowdhury BA. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017;14(9):1395-402. doi:10.1513/AnnalsATS.201606-458OC

45. Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Pulm Pharmacol Ther. 2016;40:95-103. doi:10.1016/j.pupt.2016.07.009

46. Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest. 2021;160(5):1751-63. doi:10.1016/j.chest.2021.06.049

47. Kou M, Jiao Y, Li Z, et al. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2024;80(10):1445-60. doi:10.1007/s00228-024-03720-7

48. Fleetwood K, McCool R, Glanville J, et al. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments. J Manag Care Spec Pharm. 2017;23(3-b Suppl):10.18553/jmcp.2017.23.3-b.s5. doi:10.18553/jmcp.2017.23.3-b.s5

49. Ley B, Collard HR, King TE. Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2011;183(4):431-40. doi:10.1164/rccm.201006-0894CI

50. Karman J, Wang J, Bodea C, Cao S, Levesque MC. Lung gene expression and single cell analyses reveal two subsets of idiopathic pulmonary fibrosis (IPF) patients associated with different pathogenic mechanisms. Kass DJ, ed. PLOS ONE. 2021;16(3):e0248889. doi:10.1371/journal.pone.0248889

51. Bocchino M, Agnese S, Fagone E, et al. Reactive Oxygen Species Are Required for Maintenance and Differentiation of Primary Lung Fibroblasts in Idiopathic Pulmonary Fibrosis. PLOS ONE. 2010;5(11):e14003. doi:10.1371/journal.pone.0014003

52. Shah RR, Morganroth J, Shah DR. Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives. Drug Saf. 2013;36(7):491-503. doi:10.1007/s40264-013-0048-4

53. Raschi E, Fusaroli M, Gatti M, Caraceni P, Poluzzi E, De Ponti F. Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal. Pharmaceuticals. 2022;15(5):645. doi:10.3390/ph15050645

54. Abdel-Rahman O, Bahie Eldin N, ElHalawani H. Risk of Selected Gastrointestinal and Hepatic Toxicities in Cancer Patients Treated with Nintedanib: A Meta-Analysis. Future Oncol. 2016;12(18):2163-72. doi:10.2217/fon-2016-0067

55. Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013;36(7):491-503. doi:10.1007/s40264-013-0048-4

56. Han D, Shinohara M, Ybanez MD, Saberi B, Kaplowitz N. Signal transduction pathways involved in drug-induced liver injury. Handb Exp Pharmacol. 2010;(196):267-310. doi:10.1007/978-3-642-00663-0_10

57. Kato M, Sasaki S, Nakamura T, et al. Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis. Sci Rep. 2019;9(1):12062. doi:10.1038/s41598-019-48593-4

58. Epstein Shochet G, Brook E, Eyal O, Edelstein E, Shitrit D. Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib. Am J Physiol Lung Cell Mol Physiol. 2019;316(6):L1025-L1034. doi:10.1152/ajplung.00526.2018

59. Seto Y, Inoue R, Kato M, Yamada S, Onoue S. Photosafety assessments on pirfenidone: Photochemical, photobiological, and pharmacokinetic characterization. J Photochem Photobiol B. 2013;120:44-51. doi:10.1016/j.jphotobiol.2013.01.010

60. Ikeda S, Sekine A, Baba T, et al. Low starting-dosage of nintedanib for the reduction of early termination. Respir Investig. 2019;57(3):282-5. doi:10.1016/j.resinv.2018.12.010